Comparison · NCT00498797-5b8e49d1
Vandetanib vs Placebo: Prostate Specific Antigen (PSA) Response
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vandetanib vs Placebo: Prostate Specific Antigen (PSA) Response. Trial comparisons, record NCT00498797-5b8e49d1. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00498797-5b8e49d1
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.395 | 0.264 | 0.544 | wilson | |
| Risk in group 2 | 0.674 | 0.525 | 0.795 | wilson | |
| Risk difference, group 1 minus group 2 | -0.279 | -0.458 | -0.0683 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.586 | 0.384 | 0.896 | log | |
| Odds ratio, group 1 over group 2 | 0.316 | 0.13 | 0.764 | log | |
| Number needed to treat, for one fewer participant with the outcome on Vandetanib than on Placebo | 3.58 | 2.18 | 14.6 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vandetanib | docetaxel/prednisolone/vandetanib | 17 | 43 | OG000 |
| Group 2 | Placebo | docetaxel/prednisolone/placebo | 29 | 43 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Prostate Specific Antigen (PSA) Response
- Description
- Prostate Specific Antigen (PSA) response was defined as a reduction of at least 50% from baseline at any assessment, confirmed by a second assessment 2-4 weeks after the initial response
- Time frame
PSA measurements were to be performed at screening, at baseline (>2 weeks after screening) and every 3 weeks during the study. Any response was to be confirmed 2-4 weeks after the initial assessment of a 50% fall in PSA from baseline
- Population
Source ClinicalTrials.gov
Trial
- Title
- E3-Hormone Refractory Prostrate Cancer Taxotere Combination
- NCT number
- NCT00498797
- Phases
- PHASE2
- Conditions
- Prostate Cancer, Metastatic, Hormone Refractory
- Interventions
- Zactima (vandetanib), Docetaxel, Prednisolone
- Lead sponsor
- Sanofi
- Results first posted
- 2011-05-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00498797?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00498797-5b8e49d1